Sanofi Quick Ratio 2012-2025 | SNY
Historical quick ratio values for Sanofi (SNY) over the last 10 years.
| Sanofi Quick Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets - Inventory | Current Liabilities | Quick Ratio |
| 2025-09-30 | $11.15B | $37.53B | 0.30 |
| 2025-06-30 | $31.10B | $32.99B | 0.94 |
| 2025-03-31 | $23.36B | $33.95B | 0.69 |
| 2024-12-31 | $35.88B | $31.56B | 1.14 |
| 2024-09-30 | $0.00B | 0.00 | |
| 2024-06-30 | $20.97B | $32.34B | 0.65 |
| 2024-03-31 | $0.00B | 0.00 | |
| 2023-12-31 | $22.73B | $26.19B | 0.87 |
| 2023-09-30 | $0.00B | 0.00 | |
| 2023-06-30 | $21.82B | $27.00B | 0.81 |
| 2023-03-31 | $0.00B | 0.00 | |
| 2022-12-31 | $26.41B | $25.25B | 1.05 |
| 2022-09-30 | $0.00B | 0.00 | |
| 2022-06-30 | $7.91B | $23.48B | 0.34 |
| 2022-03-31 | $0.00B | 0.00 | |
| 2021-09-30 | $0.00B | 0.00 | |
| 2021-06-30 | $24.39B | $23.05B | 1.06 |
| 2021-03-31 | $0.00B | 0.00 | |
| 2020-09-30 | $0.00B | 0.00 | |
| 2020-03-31 | $0.00B | 0.00 | |
| 2019-09-30 | $0.00B | 0.00 | |
| 2019-03-31 | $0.00B | 0.00 | |
| 2018-03-31 | $0.00B | 0.00 | |
| 2017-12-31 | $22.08B | $17.47B | 1.26 |
| 2017-09-30 | $0.00B | 0.00 | |
| 2017-06-30 | $21.81B | $18.76B | 1.16 |
| 2017-03-31 | $0.00B | 0.00 | |
| 2016-12-31 | $21.91B | $18.19B | 1.21 |
| 2016-09-30 | $0.00B | 0.00 | |
| 2016-06-30 | $17.25B | $17.22B | 1.00 |
| 2016-03-31 | $0.00B | 0.00 | |
| 2015-09-30 | $0.00B | 0.00 | |
| 2015-06-30 | $16.44B | $18.03B | 0.91 |
| 2014-06-30 | $18.64B | $19.48B | 0.96 |
| 2013-06-30 | $18.22B | $17.80B | 1.02 |
| 2012-06-30 | $19.10B | $20.66B | 0.92 |
| 2012-03-31 | $0.00B | 0.00 | |
| 2011-12-31 | $20.62B | $18.92B | 1.09 |
| 2011-09-30 | $0.00B | 0.00 | |
| 2011-06-30 | $23.56B | $23.10B | 1.02 |
| 2011-03-31 | $0.00B | 0.00 | |
| 2010-12-31 | $29.29B | $15.62B | 1.88 |
| 2010-09-30 | $0.00B | 0.00 | |
| 2010-06-30 | $25.36B | $15.40B | 1.65 |
| 2010-03-31 | $0.00B | 0.00 | |
| 2009-12-31 | $27.10B | $17.29B | 1.57 |
| 2009-09-30 | $0.00B | 0.00 | |
| 2009-06-30 | $19.42B | $14.69B | 1.32 |
| 2009-03-31 | $0.00B | 0.00 | |
| 2008-12-31 | $17.38B | $13.75B | 1.26 |
| 2008-09-30 | $0.00B | 0.00 | |
| 2008-06-30 | $12.75B | $14.01B | 0.91 |
| 2008-03-31 | $0.00B | 0.00 | |
| 2007-12-31 | $12.10B | $13.25B | 0.91 |
| 2007-09-30 | $0.00B | 0.00 | |
| 2007-06-30 | $11.44B | $13.18B | 0.87 |
| 2007-03-31 | $0.00B | 0.00 | |
| 2006-12-31 | $10.68B | $12.91B | 0.83 |
| 2006-09-30 | $0.00B | 0.00 | |
| 2006-06-30 | $10.92B | $17.89B | 0.61 |
| 2006-03-31 | $0.00B | 0.00 | |
| 2005-12-31 | $12.07B | $19.20B | 0.63 |
| 2005-09-30 | $0.00B | 0.00 | |
| 2005-06-30 | $12.37B | $20.53B | 0.60 |
| 2005-03-31 | $0.00B | 0.00 | |
| 2004-12-31 | $11.78B | $18.67B | 0.63 |
| 2004-06-30 | $7.50B | $3.44B | 2.18 |
| 2003-12-31 | $7.86B | $3.27B | 2.41 |
| 2003-06-30 | $5.36B | $2.72B | 1.97 |
| 2002-12-31 | $5.51B | $2.67B | 2.06 |
| 2002-06-30 | $4.82B | $2.42B | 1.99 |
| 2001-12-31 | $5.67B | $2.66B | 2.14 |
| 2001-06-30 | $4.37B | $1.91B | 2.29 |
| 2000-12-31 | $4.36B | $2.11B | 2.07 |
| 1999-12-31 | $3.88B | $2.23B | 1.74 |
| 1998-12-31 | $3.40B | $2.29B | 1.48 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $119.584B | $44.458B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1005.472B | 48.37 |
| Johnson & Johnson (JNJ) | United States | $492.436B | 19.69 |
| AbbVie (ABBV) | United States | $388.966B | 23.29 |
| Roche Holding AG (RHHBY) | Switzerland | $340.187B | 0.00 |
| Novartis AG (NVS) | Switzerland | $298.992B | 15.85 |
| Merck (MRK) | United States | $274.338B | 12.78 |
| Novo Nordisk (NVO) | Denmark | $262.587B | 15.40 |
| Pfizer (PFE) | United States | $144.872B | 7.96 |
| Bayer (BAYRY) | Germany | $44.366B | 7.79 |
| Innoviva (INVA) | United States | $1.464B | 7.33 |